The tolerance and pharmacokinetics of clinafloxacin (CI-960) in healthy subjects.
The single-dose tolerance and pharmacokinetics of clinafloxacin, a new fluoroquinolone antibacterial agent, were evaluated in healthy volunteers. Single oral doses of 25, 50, 100, and 200 mg were well tolerated. Adverse events after placebo and clinafloxacin were similar, with mild drowsiness, dizziness, headache, and rash being reported most frequently. The frequency and intensity of side-effects did not increase with dose. Clinafloxacin was rapidly absorbed, with Cmax occurring at approximately 40 min postdose. Plasma concentrations increased proportionately and, following 100 or 200 mg doses, remained above MIC90s required for most nosocomial pathogens for at least 12 h. Clinafloxacin elimination half-life averaged 5.2 h and renal clearance was approximately 200 mL/min. About 50% of the administered dose was excreted unchanged in the urine.
Bron
N J
NJ
Department of Clinical Pharmacology, Parke-Davis Pharmaceutical Research, Division of Warner-Lambert Company, Eastleigh, UK.
Dorr
M B
MB
Mant
T G
TG
Webb
C L
CL
Vassos
A B
AB
D000328:Adult; D000890:Anti-Infective Agents / Q000009:adverse effects* / Q000097:blood / Q000493:pharmacokinetics*; D004305:Dose-Response Relationship, Drug; D005069:Evaluation Studies as Topic; D024841:Fluoroquinolones; D006801:Humans; D008297:Male; D015363:Quinolones / Q000009:adverse effects* / Q000097:blood / Q000493:pharmacokinetics*
D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D015363:Quinolones; C057477:clinafloxacin